Abstract Purpose of Review Familial hypercholesterolemia (FH) and hyperlipoproteinemia
(a) are relatively common disorders, posing a significant health burden due to increased risk …

Background: The prevalence of familial hypercholesterolemia is 1 in 250, but< 10% of
patients are diagnosed. Cascade testing enables early detection of cases through …

Background Little is known about prevalence, awareness, and control of familial
hypercholesterolemia (FH) in the United States. Objective To address these knowledge …

In the 15 years following the release of the first complete human genome sequences, our
understanding of rare and common genetic variation as determinants of cardiovascular …

Objective There is no coordinated cascade testing program for familial hypercholesterolemia
(FH) in the US We evaluated the contemporary cost-effectiveness of cascade genetic testing …

Background: The implications of secondary findings detected in large-scale sequencing
projects remain uncertain. We assessed prevalence and penetrance of pathogenic familial …

Familial hypercholesterolemia (FH) is the most common genetic disease which accelerates
the development of premature coronary artery disease (CAD) in young adults if remains …

Objectives To identify clinically actionable genetic variants from targeted sequencing of 68
disease-related genes, estimate their penetrance, and assess the impact of disclosing …

Background Oral administration of statins for the treatment of familial hypercholesterolemia
results in poor therapeutic outcomes and patient compliance. An alternative administration …

Severe hypercholesterolemia/possible familial hypercholesterolemia (FH) is relatively
common but underdiagnosed and undertreated. We investigated whether implementing …